Market closedNon-fractionalADR
BeiGene/BGNE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About BeiGene
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Ticker
BGNE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Grand cayman, Cayman Islands
Employees
10,000
Website
www.beigene.com
BeiGene Metrics
BasicAdvanced
$16B
Market cap
-
P/E ratio
-$7.57
EPS
0.60
Beta
-
Dividend rate
Price and volume
Market cap
$16B
Beta
0.6
52-week high
$229.57
52-week low
$126.97
Average daily volume
4
Financial strength
Current ratio
2.077
Quick ratio
1.839
Long term debt to equity
5.923
Total debt to equity
30.532
Management effectiveness
Return on assets (TTM)
-13.50%
Return on equity (TTM)
-20.87%
Return on investment (TTM)
-18.48%
Valuation
Price to revenue (TTM)
5.799
Price to book
4.24
Price to tangible book (TTM)
4.847
Growth
Revenue change (TTM)
77.42%
Earnings per share change (TTM)
58.94%
3-year revenue growth (CAGR)
99.67%
What the Analysts think about BeiGene
Analyst Ratings
Majority rating from 23 analysts.
BeiGene Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$752M
18.47%
Net income
-$251M
-31.67%
Profit margin
-33.40%
-42.33%
BeiGene Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.64
$2.01
-$3.53
-$2.41
-
Expected
-$2.81
-$3.11
-$3.96
-$2.54
-$2.33
Surprise
29.50%
-164.71%
-10.78%
-5.28%
-
BeiGene News
AllArticlesVideos
BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Seeking Alpha·1 month ago
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
Business Wire·1 month ago
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BeiGene stock?
BeiGene (BGNE) has a market cap of $16B as of July 27, 2024.
What is the P/E ratio for BeiGene stock?
The price to earnings (P/E) ratio for BeiGene (BGNE) stock is 0 as of July 27, 2024.
Does BeiGene stock pay dividends?
No, BeiGene (BGNE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next BeiGene dividend payment date?
BeiGene (BGNE) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene?
BeiGene (BGNE) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell BeiGene stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.